Skip To Main Content
Parameswaran Hari on Muck Rack

Parameswaran Hari

As seen in: Nature, Wiley, Educational Studies, The BMJ, The New England Journal of Medicine, Healio, Future Medicine, ONCOLOGY journal, CURE Magazine, The ASCO Post and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Parameswaran

Contact Parameswaran, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

|
By Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo
| The BMJ Verified
Immune cell therapies and immune cell engineering Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Open in Who Shared Issue with article?

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk - Blood Cancer Journal

|
By Natalie S. Callander, Jonathan Kaufman, Jacob P. Laubach, Timothy Schmidt, Brandi N. Reeves, Binod Dhakal, Saurabh Chhabra, Bhagirathbhai Dholaria, Parameswaran Hari, Sarah A Holstein, Andrzej J. Jakubowiak, Luciano Costa Verified, Saad Usmani, Paul Richardson
| Nature Verified
Abstract In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).
Open in Who Shared Issue with article?

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing - Blood Cancer Journal

|
By Fumou Sun, Anita D’Souza, Binod Dhakal, Parameswaran Hari, Yong Li, Fenghuang Zhan, Siegfried Janz, Jing Dong
| Nature Verified
Abstract Multiple myeloma (MM) is a heterogenous plasma cell malignancy, for which the established prognostic models exhibit limitations in capturing the full spectrum of outcome variability. Leveraging single-cell RNA-sequencing data, we developed a novel plasma cell gene signature.
Open in Who Shared Issue with article?
See all 23 licensed articles (31 Total)